RxDoctor Payments Data

Kelly Sparkman

Psychiatric/Mental Health · Beaumont, TXNPI 1972934313

Payments from drug & device makers

$1,920in general payments, 2019–2025

Across 107 payments — averaging $17.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sunovion Pharmaceuticals Inc.$576
  • AbbVie$330
  • Neurocrine Biosciences, Inc.$279
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$228
  • Teva Pharmaceuticals USA, Inc.$155
  • Johnson & Johnson$137
  • plus $215 from 5 others

What the payments were for

  • Food & beverage$1,87398%
  • Education$472%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,920 in reported general payments places this provider in the 70th percentile of 2,724 psychiatric/mental health providers in Texas.

See all psychiatric/mental health providers in Texas

Medicare billing

Part B allowed, 2024
$14,996
Medicare patients
43
Services billed
302

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate34$282,266
Austedo XrDeutetrabenazine20$153,144
Invega SustennaPaliperidone Palmitate36$128,565
AustedoDeutetrabenazine14$91,203
VraylarCariprazine Hcl40$61,919
Abilify MaintenaAripiprazole14$44,896
Lurasidone Hcl54$18,844
Aripiprazole99$9,311
Olanzapine86$3,646
Haloperidol Decanoate51$3,345
Haloperidol119$3,342
Buspirone Hcl165$3,163
Quetiapine Fumarate129$2,845
Benztropine Mesylate136$2,363
Fluoxetine Hcl166$2,067

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$279$282,26634 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo$155$244,34734 claims
Johnson & JohnsonInvega Sustenna$137$128,56536 claims
AbbVieVraylar$330$61,91940 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$34$44,89614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,724 psychiatric/mental health providers in Texas.

Other psychiatric/mental health in Beaumont

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →